16α-[18F]氟-17β-雌二醇正电子发射断层扫描/计算机断层扫描评估新诊断转移性乳腺癌雌激素受体状态的临床有效性
这项前瞻性多中心试验纳入200例新诊断转移性乳腺癌患者,评估[18F]FES-PET定性全身评估和定量摄取预测转移灶免疫组化ER表达的诊断准确性。定性评估在181例可评估患者中灵敏度95%、特异度80%、PPV 93%、NPV 85%;定量评估在156例可评估患者中灵敏度/特异度91%/69%、PPV/NPV 90%/71%。作者结论认为[18F]FES-PET可考虑作为活检的替代方法来确定ER状态。
要点
- 定性全身[18F]FES-PET预测转移灶ER表达的灵敏度95%、特异度80%。
- 定量[18F]FES摄取预测对应转移灶ER免疫组化的灵敏度/特异度为91%/69%。
- 作者认为定性[18F]FES-PET可考虑作为转移灶活检的替代方法确定ER状态。
核心结论
- 在这项迄今最大的前瞻性系列中,作者确立了[18F]FES-PET确定转移性乳腺癌肿瘤ER状态的临床有效性。
- 鉴于定性评估全身[18F]FES-PET的高诊断准确性,作者认为这种无创影像模态可考虑作为新诊断转移性乳腺癌中转移灶活检的替代方法来确定ER状态。
研究设计与样本
- 前瞻性多中心试验,200例新诊断转移性乳腺癌患者接受包括分子影像在内的广泛检查。
- 本亚分析将活检转移灶的ER表达与定性全身[18F]FES-PET评估及对应转移灶的定量[18F]FES摄取相关联。
- 进行了关于[18F]FES-PET诊断性能的综述和Meta分析。
主要发现
- 定性全身[18F]FES-PET预测活检转移灶ER表达:在200例中181例可评估患者中,灵敏度95%(95% CI,89至97),特异度80%(66至89),阳性预测值93%(87至96),阴性预测值85%(72至92)。
- 定量[18F]FES摄取预测对应转移灶ER免疫组化:在200例中156例可评估患者中,灵敏度/特异度91%/69%,PPV/NPV 90%/71%。
- 骨转移中PPV/NPV为92%/81%。
- Meta分析加入本研究数据后,与既往研究相比诊断性能提高且95% CI缩窄,灵敏度/特异度均为86%(分别为81至90和73至93)。
临床怎么用
- 作者认为定性评估全身[18F]FES-PET可考虑作为新诊断转移性乳腺癌中转移灶活检的替代方法来确定ER状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[18F]fluoro-17β-estradiol positron emission tomography ([18F]FES-PET) is increasingly used for this purpose. To establish the clinical validity of the [18F]FES-PET, we studied the diagnostic accuracy of qualitative and quantitative [18F]FES-PET assessment to predict ER expression by immunohistochemistry in a metastasis. METHODS: In a prospective multicenter trial, 200 patients with newly diagnosed MBC underwent extensive workup including molecular imaging. For this subanalysis, ER expression in the biopsied metastasis was related to qualitative whole-body [18F]FES-PET evaluation and quantitative [18F]FES uptake in the corresponding metastasis. A review and meta-analysis regarding [18F]FES-PET diagnostic performance were performed. RESULTS: Whole-body [18F]FES-PET assessment predicted ER expression in the biopsied metastasis with good accuracy: a sensitivity of 95% (95% CI, 89 to 97), a specificity of 80% (66 to 89), a positive predictive value (PPV) of 93% (87 to 96), and a negative predictive value (NPV) of 85% (72 to 92) in 181 of 200 evaluable patients. Quantitative [18F]FES uptake predicted ER immunohistochemistry in the corresponding metastasis with a sensitivity/specificity of 91%/69% and a PPV/NPV of 90%/71% in 156 of 200 evaluable patients. For bone metastases, PPV/NPV was 92%/81%. Meta-analysis with addition of our data has increased diagnostic performance and narrowed the 95% CIs compared with previous studies with a sensitivity/specificity of both 86% (81 to 90 and 73 to 93, respectively). CONCLUSION: In this largest prospective series so far, we established the clinical validity of [18F]FES-PET to determine tumor ER status in MBC. In view of the high diagnostic accuracy of qualitatively assessed whole-body [18F]FES-PET, this noninvasive imaging modality can be considered a valid alternative to a biopsy of a metastasis to determine ER status in newly MBC (ClinicalTrials.gov identifier: NCT01957332).
引用
- van Geel JJL, Boers J, Elias SG, et al. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. J Clin Oncol. 2022. PMID: 35584346. doi:10.1200/JCO.22.00400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。